In 2024, Payers Refined Specialty Management Tactics By Taking More Active Role
-
Dec 12, 2024
As more specialty drugs and cell and gene therapies launch onto the U.S. market, payers are increasingly deploying utilization management (UM) tactics in order to focus more on targeted clinical criteria to manage them. Other strategies include shifting medical benefit drugs to the pharmacy benefit and implementing value-based contracts (VBCs). AIS Health, a division of MMIT, asked industry experts about these approaches and others that payers are taking in their management of specialty drugs for our annual look back at the year. (Editor’s note: These comments have been edited for length and clarity.) Read more© 2024 MMIT
The Latest
Meet Our Reporters
Meet Our Reporters
GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND
Sign up for publications to get unmatched business intelligence delivered to your inbox.